Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits. Large vector doses also trigger an immune response as a significant fraction of the vectors fails to traffic efficiently to the nucleus and is targeted for degradation by the host cell proteasome machinery. We have reported that epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) signaling negatively affects transduction by AAV2 vectors by impairing nuclear transport of the vectors. We have also observed that EGFR-PTK can phosphorylate AAV2 capsids at tyrosine residues. Tyrosine-phosphorylated AAV2 vectors enter cells efficiently but fail to transduce effectively, in part because of ubiquitination of AAV capsids followed by proteasome-mediated degradation. We reasoned that mutations of the surface-exposed tyrosine residues might allow the vectors to evade phosphorylation and subsequent ubiquitination and, thus, prevent proteasome-mediated degradation. Here, we document that site-directed mutagenesis of surface-exposed tyrosine residues leads to production of vectors that transduce HeLa cells ≈10-fold more efficiently in vitro and murine hepatocytes nearly 30-fold more efficiently in vivo at a log lower vector dose. Therapeutic levels of human Factor IX (F.IX) are also produced at an ≈10-fold reduced vector dose. The increased transduction efficiency of tyrosine-mutant vectors is due to lack of capsid ubiquitination and improved intracellular trafficking to the nucleus. These studies have led to the development of AAV vectors that are capable of high-efficiency transduction at lower doses, which has important implications in their use in human gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous mutagenesis and biophysical studies have reported the importance of some of these residues in virus assembly, production (Grieger et al., 2006; Wu et al., 2000), infectivity (Zhong et al., 2008), and pH-induced changes during trafficking (Nam et al., 2011; Salganik et al., 2012).”
From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as Zhong et al., 2008
In the citing paper
“Therefore, mutation of surface tyrosine has been suggested, which resulted in reduced presentation of AAV capsid, decreased T-cell toxicity, and required therapeutic dose [100, 225, 229].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [229]
In the citing paper
“Since surface-exposed residues on AAV capsids can be ubiquitinated through phosphorylation, mutations of these residues (e.g. tyrosine, lysine, serine) to reduce the likelihood of ubiquitination can generate novel capsids with reduced ubiquitination, antigen presentation, and activated cellular immunity (92 -99).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [93]
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648 · cited 1×
“The icosahedral two-, three- and fivefold related VP3 monomers were generated by applying icosahedral symmetry operators to a reference monomer, using the program O (46) on a Silicon graphics Octane workstation.”
MethodManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Self-citationXiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells
Muzyczka, N. (1992) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-75608-5_5 · Cited by 754 · cited 1×
“T adeno-associated virus 2 (AAV2) is a nonpathogenic human parvovirus, which has gained attention as an alternative to the more commonly used retrovirus- and adenovirusbased vectors for gene transfer and gene therapy (1, 2).”
BackgroundSelf-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“It was concluded that this CD8 T cell response to input capsid eliminated AAV2-transduced hepatocytes (43).”
BackgroundαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Cited by
Items 401–500 of 567
Locke, M., Ussher, J. E., Mistry, R. M., Taylor, J. A., & Dunbar, P. R. (2011) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2011.0153 · Cited by 13
“39 Given the cytotoxicity of rAAV2 in human ASCs we investigated the utility of rAAV6 tyrosine capsid mutants for increasing transduction efficiency.”
Fakhiri, J., Linse, K.-P., Mietzsch, M., Xu, M., Schneider, M. A., Meister, M. A., Schildgen, O., Schnitzler, P., Söderlund‐Venermo, M., Agbandje‐McKenna, M., et al. (2020) · Journal of Virology · doi:10.1128/jvi.00170-20 · Cited by 12
Self-citationReprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer
Pandya, M., Britt, K., Hoffman, B. E., Ling, C., & Aslanidi, G. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000093 · Cited by 13
Aktaş, Z., Rao, H., Slauson, S. R., Gabelt, B. T., Larsen, I. V., Sheridan, R. T. C., Herrnberger, L., Tamm, E. R., Kaufman, P. L., & Brandt, C. R. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22074 · Cited by 12
“The proteasome-mediated inhibition of AAV vector transduction involves EGFR-PTK–mediated phosphorylation of surfaceexposed tyrosine residues on the capsid.69–72 Tyrosine phosphorylated AAV capsids are then ubiquitinated and the capsids traffic to proteasomes where they are destroyed.73 In an effort to increase transdu…”
InfluentialGene editing technology: Towards precision medicine in inherited retinal diseases
Ballios, B. G., Pierce, E. A., & Huckfeldt, R. M. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1887903 · Cited by 13
Biber, J., Jabri, Y., Glänzer, S., Dort, A., Hoffelner, P., Schmidt, C. Q., Bludau, O., Pauly, D., & Grosche, A. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03045-3 · Cited by 12
“…cell-specificity of AAV-mediated transduction, the Y445F variant of the ShH10 capsid could be considered, as it has been shown to hit as much as 50% of all Müller cells [69], whereas the original ShH10 capsid used here was only able to transduce 22% of Müller cells upon intravitreal injection [31].”
BackgroundOptogenetic Control of Neural Circuits in the Mongolian Gerbil
Keplinger, S., Beiderbeck, B., Michalakis, S., Biel, M., Grothe, B., & Kunz, L. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00111 · Cited by 11
“Moreover, phosphorylation of surface-exposed tyrosine residues in the AAV capsid has been reported to contribute to targeting to the proteasome for degradation (Zhong et al., 2008).”
BackgroundLopes‐Pacheco, M., Kitoko, J. Z., Morales, M. M., Petrs‐Silva, H., & Rocco, P. R. M. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.09.015 · Cited by 11
Proteosomal degradation impairs transcytosis of AAV vectors from suprachoroidal space to retina
Ding, K., Shen, J., Hackett, S. F., Khan, M., & Campochiaro, P. A. (2021) · Gene Therapy · doi:10.1038/s41434-021-00233-1 · Cited by 11
Retinal Gene Therapy Using Adeno-Associated Viral Vectors: Multiple Applications for a Small Virus
Hauswirth, W. W. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2530 · Cited by 12
“A. Srivastava has shown that changing phosphorylatable AAV surface capsid amino acids, for example, tyrosines, to nonphosphorylatable residues, for example, phenyalanines, enhances transduction efficiency in vitro and in vivo (Zhong et al., 2008a,b).”
BackgroundSorroza-Martinez, L., Pelletier, M., Guay, D., & Gaillet, B. (2024) · Current Gene Therapy · doi:10.2174/0115665232294935240826061311 · Cited by 10
The amazing AAV capsids: Into the structure-verse
Hsi, J., Mietzsch, M., & McKENNA, R. V. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101629 · Cited by 12
Strategies of AAV capsid engineering for targeted delivery to brain, muscle, and retina
Xu, X. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1750807 · Cited by 10
Systemic Delivery of Adeno-Associated Viral Vectors in Mice and Dogs
Wasala, L. P., Hakim, C. H., Yue, Y., Yang, N. N., & Duan, D. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9065-8_18 · Cited by 11
Parvovirus particles and movement in the cellular cytoplasm and effects of the cytoskeleton
Lyi, S. M., Tan, M. J. A., & Parrish, C. R. (2014) · Virology · doi:10.1016/j.virol.2014.04.003 · Cited by 10
“AAV2 capsids may also be modified by ubiquitin addition to surface exposed tyrosines (Tyr), and mutating one or more of the several Tyr on the capsid surface can enhance transduction due to alterations that capsid modification (Zhong et al., 2008a; Zhong et al., 2008b).”
Adeno-Associated Viral Gene Therapy for Retinal Disorders
Silva, S. R. D., McClements, M. E., Hankins, M. W., & MacLaren, R. E. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_9 · Cited by 11
Complement yourself: transcomplementation rescues partially folded mutant proteins
Cebotaru, L., & Guggino, W. B. (2014) · Biophysical Reviews · doi:10.1007/s12551-014-0137-3 · Cited by 11
“Also, a number of groups have generated novel capsids not found in nature that improve the tropism for specific tissues (Zhong et al. 2008). rAAV vectors transduce a variety of cell types in several animal models, including rabbit and monkey lung (Beck et al. 1999, 2002).”
BackgroundAdeno-associated viral vectors deliver gene vaccines
Wei, L., Yu, P., Wang, H., & Liu, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117010 · Cited by 10
Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy
Dai, L., & Du, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.961848 · Cited by 9
“Currently, studies have confirmed that these new site-mutated AAVs, such as sitedirected mutagenesis (tyrosine to phenylalanine), could evade the immune response due to the pre-existing neutralizing antibodies and improve the AAV tropism and transduction efficiency as well (Wu et al., 2006; Zhong et al., 2008; Lompre…”
BackgroundEngineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS
Sandoval, I. M., Kelley, C. M., Bernal-Conde, L. D., Steece‐Collier, K., Marmion, D. J., Davidsson, M., Crosson, S. M., Boye, S. L., Boye, S. L., & Manfredsson, F. P. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102332 · Cited by 9
“28,29 To assess the effect of these mutations on overcoming age-related impairments in transduction, we compared these variants head-to-head with WT AAV2 using a variety of important parameters following a single injection into the striatum, a relevant anatomical target for several…”
Lim, Y., Campochiaro, P. A., & Green, J. J. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.12.010 · Cited by 10
Zhang, X., Chai, Z., Samulski, R. J., & Li, C. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.193 · Cited by 9
Wang, H., Li, R., Sadekar, S., Kamath, A. V., & Shen, B. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101326 · Cited by 8
Gene therapy for hemophilia: advancing beyond the first clinical success
Monahan, P. E., & Gui, T. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328363c1a1 · Cited by 9
“After host cell entry, AAV capsids may be subject to cytoplasmic phosphorylation/ ubiquitination, resulting in shunting to proteasomes for degradation rather than trafficking to the nucleus [27].”
BackgroundChen, M. Y., Chen, W., Tong, J., Ho, M., & Suh, J. (2021) · Virology · doi:10.1016/j.virol.2021.08.010 · Cited by 8
Development of an adipose-tropic AAV capsid ablating liver tropism
Huang, W., Bates, R., Appana, B., Mohammed, T., & Cao, L. (2024) · iScience · doi:10.1016/j.isci.2024.110930 · Cited by 8
Optimizing the adeno-associated Viral Vector System: a Brief Summary
Hacker, U. T., & Büning, H. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.69 · Cited by 8
Sosa, I., Estrada, A. H., Winter, B., Erger, K. E., & Conlon, T. J. (2016) · American Journal of Veterinary Research · doi:10.2460/ajvr.77.2.156 · Cited by 8
Preparation and Administration of Adeno-associated Virus Vectors for Corneal Gene Delivery
Song, L., Bower, J. J., & Hirsch, M. L. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0599-8_7 · Cited by 8
Sherpa, C., & Grice, S. F. J. L. (2020) · Current HIV Research · doi:10.2174/1570162x18666200210121339 · Cited by 8
Wu, J., Hua, Y., Zheng, Y., Liu, X., & Li, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13081994 · Cited by 7
“Targeted tyrosine (Y) and threonine (T) substitutions, residues implicated in ubiquitin-mediated intracellular trafficking, demonstrably enhance AAV2 transduction efficiency [45].”
Araujo, A. E., Bentler, M., Garmendia, X. P., Kaleem, A., Fabian, C., Morgan, M. A., Hacker, U. T., & Büning, H. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.114 · Cited by 7
“50 They reported the exchange of distinct amino acid residues within the capsid proteins, that is, tyrosine to phenylalanine, threonine or serine to valine, lysine to glutamic acid, and reduced proteasomal degradation of capsids.”
Nakahama, R., Saito, A., Nobe, S., Togashi, K., Suzuki, I., Uematsu, A., & Emoto, K. (2022) · Molecular Brain · doi:10.1186/s13041-022-00957-0 · Cited by 7
“It has been reported that missense mutations on the AAV capsid remarkably enhanced transgene expression efficiency [11, 12].”
BackgroundPEG-mediated transduction of rAAV as a platform for spatially confined and efficient gene delivery
Zou, L., Wang, J., Fāng, Y., & Tian, H. (2022) · Biomaterials Research · doi:10.1186/s40824-022-00322-1 · Cited by 7
Gene Therapy for Paediatric Homozygous Familial Hypercholesterolaemia
Graves, L. E., Horton, A., Alexander, I. E., & Srinivasan, S. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.01.017 · Cited by 7
Wang, H., Kwak, S. E., Zheng, A., Arias, E. B., Pan, X., Duan, D., & Cartee, G. D. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00010.2024 · Cited by 7
On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors
de la Mota, S., Suchet, L., van Wijk, M., Stibbs, D. J., Couto, P. S., & Rafiq, Q. A. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108907 · Cited by 6
Gene Therapy: Contest between Adeno-Associated Virus and Host Cells and the Impact of UFMylation
Maurya, S., & Jayandharan, G. R. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00512 · Cited by 6
Duwat, C., Léal, P., Vautheny, A., Aurégan, G., Joséphine, C., Gaillard, M., Hérard, A., Jan, C., Gipchtein, P., Mitja, J., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106116 · Cited by 7
Huang, X., Wang, X., Li, L., Qizhao, W., Xu, W., Wu, W., Xie, X., & Diao, Y. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17858 · Cited by 6
Chen, Z., Yu, Q., Jia, W., Yu, X. Y., Yu, D., Yang, M., Wang, L., Ling, C., & Zhu, L. (2020) · The FASEB Journal · doi:10.1096/fj.201902875r · Cited by 6
Brown, B. L., Zalla, R. M., Shepard, C. T., Howard, R. M., Kopechek, J. A., Magnuson, D. S. K., & Whittemore, S. R. (2021) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2021.635921 · Cited by 6
Identification of Novel Retinal Pericyte-Targeting rAAV Vectors Through Directed Evolution
Patel, D. D., Marsic, D., Periasamy, R., Zolotukhin, S., & Lipinski, D. M. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.8.28 · Cited by 6
“43 As a result, it is not clear whether the increased efficiency of an improved variant with mutant VR IV or VR V is due to the particular motif present in the VR or just to the Y444F or Y500F mutation.”
Self-citationZarbin, M. A., Leary, J. F., Montemagno, C. D., Ritch, R. H., & Humayun, M. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00036-9 · Cited by 7
AAV-mediated human CNGB3 restores cone function in an all-cone mouse model of CNGB3 achromatopsia
Zhang, Y., Wang, S., Xu, M., Pang, J., Yuan, Z., & Zhao, C. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.33.20190056 · Cited by 7
Gene Therapy Methods and Their Applications in Neurological Disorders
Li, M., & Snider, B. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00001-6 · Cited by 9
mGem: AAV, from almost a virus to an awesome vector—or is it?
Srivastava, A. (2026) · mBio · doi:10.1128/mbio.02957-25 · Cited by 5
“…(67), and threonine (68) residues, which serves as a signal for ubiquitination at lysine (69) residues, followed by proteasome-mediated degradation (70, 71), which negatively impacts not only on the transduction efficiency, but the broken down peptides also trigger a cytotoxic T-cell response (72).”
Self-citationManufacturing Considerations and Challenges for AAV Ocular Gene Therapy
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Rivers, H. M., Feng, S., Shah, D., & Slater, N. K. H. (2021) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-76367-1_22 · Cited by 5
Rapid characterization of adeno-associated virus (AAV) capsid proteins using microchip ZipChip CE-MS
Smith, J., Carillo, S., Kulkarni, A., Redman, E., Yu, K., & Bones, J. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-05097-5 · Cited by 5
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Viral Vector Technologies and Strategies: Improving on Nature
Croze, R. H., Kotterman, M. A., Burns, C. H., Schmitt, C. E., Quezada, M., Schaffer, D. V., Kirn, D. H., & Francis, P. J. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000361 · Cited by 5
Improving retinal vascular endothelial cell tropism through rational rAAV capsid design
Periasamy, R., Patel, D. D., Boye, S. L., Boye, S. L., & Lipinski, D. M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285370 · Cited by 5
“capsid through rational design or library screening has become a common approach to further 74 alter cellular tropism, increase tissue penetrance, or provide the ability to evade cellular 75 proteolytic degradation and host immunity [13-15].”
BackgroundQiao, C., Li, C., Zhao, C., Li, J., Bian, T., Grieger, J. C., Li, J., Samulski, R. J., & Xiao, X. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.176 · Cited by 5
“Zhong et al. (2008a) hypothesized that mutations of the surface-exposed tyrosine residues might allow the vectors to evade phosphorylation, subsequent ubiquitination, and prevent proteasomemediated degradation.”
BackgroundInfluentialAn Adeno-Associated Virus Vector Efficiently and Specifically Transduces Mouse Skeletal Muscle
Murakami, I., Takeuchi, T., Mori‐Uchino, M., Mori, S., Fujii, T., Aoki, D., Nakagawa, K., & Kanda, T. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9369-z · Cited by 5
“addition to the previous reports concerning the transduction of the liver and retina [ 29 , 36, 37], the tyrosine mutation was also effective in the skeletal muscle in the context of the hybrid capsid.”
BackgroundResultInfluentialI Am Here: It Took a Global Village
Agbandje‐McKenna, M. (2021) · Annual Review of Virology · doi:10.1146/annurev-virology-091919-104940 · Cited by 5
Self-citationAdeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch37 · Cited by 5
Pacak, C. A., Suzuki‐Hatano, S., Khadir, F., Daugherty, A. L., Sriramvenugopal, M., Gosiker, B. J., Kang, P. B., & Cade, W. T. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04626-1 · Cited by 5
“Systemic AAV delivery is complicated by factors such as vector genome (vg) uptake by non-target tissues and vector waste due to ubiquitination and autophagic degradation pathway activation following endocytosis, leading to the current need for high intravenous (IV) doses of AAV [7].”
BackgroundInfluentialShiraishi, Y., Adachi, T. K., Cacicedo, J. M., & Ido, Y. (2022) · The FASEB Journal · doi:10.1096/fj.202200840rr · Cited by 4
Research Status and Applications of Adeno‐Associated Virus
Xia, K., Liu, S., Wu, Z., & Jiang, J. (2024) · ChemBioChem · doi:10.1002/cbic.202400856 · Cited by 4
Recombinant adeno-associated viruses as a gene delivery vehicle for the use in molecular medicine
Usman, N., & Ребриков, Д. В. (2021) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2021.051 · Cited by 4
Yuan, Y., Kong, W., Liu, X., & Shi, G. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220405135135 · Cited by 4
The significance of triple-capsid-mutant AAV8 for treatment of Sanfilippo Syndrome Type B
Ashby, F. J., & Heldermon, C. D. (2022) · Archives of Stem Cell and Therapy · doi:10.46439/stemcell.3.013 · Cited by 4
“Vector efficiency has previously been improved preclinically by a combination of selective evolution of capsids [39–41], site-directed mutagenesis [42,43], capsid shuffling and chimerism [44–46], and even deep-learning simulation [47].”
BackgroundHassan, S., Hsu, Y., Thompson, J. M., Kalmanek, E., VandeLune, J. A., Stanley, S., & Drack, A. V. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1304819 · Cited by 4
Viral Vectors for Delivery of Antiviral Sequences
Arbuthnot, P. B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-410518-8.00004-1 · Cited by 4
Talla, V., & Koilkonda, R. D. (2020) · eNeuro · doi:10.1523/eneuro.0320-19.2020 · Cited by 4
“Klf4-KO can be easily achieved in RGCs and ON of double floxed Klf4 mice by intravitreal injection of AAV2 Cre recombinase virus (Zhong et al., 2008), which allows to study the effect of Klf4-KO specifically in RGC neurons.”
BackgroundBiologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease
Zhu, S., Zhang, J., Jiang, X., Peng, C., Liu, H., & Qian, F. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115773 · Cited by 3
Poller, W. C., Rother, M., Skurk, C., & Scheibenbogen, C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01762.x · Cited by 3
“, 2006) where vector dose reduction by use of advanced vector systems has been identified as a key determinant of long-term stability (Herzog et al., 2002; Grimm et al., 2008; Zhong et al., 2008).”
BackgroundGene Therapy: Use of Viruses as Vectors
Nance, M. E., & Duan, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95711-8 · Cited by 3
Gene Therapy for Retinal Diseases
Gopinath, C., Sarkar, S., & Ghosh, A. (2021) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-15-9184-6_30 · Cited by 3
Zhu, J., Qin, T., Wei, L., Chen, F., Ding, Y., Zhang, Q., & Dang, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-4426 · Cited by 3
“AAV vectors have been shown to induce long-term expression of transgenes in mice (23), suggesting that AAV vectors can effectively transduce to a variety of target tissues in animal models, including the liver and retina, as well as the myocardium and central nervous system.”
BackgroundPires-Ferreira, D., Martini, S. V., de Oliveira, H. D., da Silva, A. L., Shenoy, S., Chen, D., Simon, V., Han, E., West, N. E., Suk, J. S., et al. (2023) · Cellular Physiology and Biochemistry · doi:10.33594/000000660 · Cited by 3
AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy
Jacobs, R., Dogbey, D. M., Mnyandu, N., Neves, K., Barth, S., Arbuthnot, P. B., & Maepa, M. B. (2023) · Microorganisms · doi:10.3390/microorganisms11122985 · Cited by 3
“Hence, the mutation of the surface-exposed tyrosine residue can reduce T-cell activity and the associated toxicity [156,157].”
BackgroundNakai, H. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_23 · Cited by 3
Recombinant Adeno-Associated Virus Serotype 6 Efficiently Transduces Primary Human Melanocytes
Sheppard, H. M., Ussher, J. E., Verdon, D. J., Chen, J. H., Taylor, J. A., & Dunbar, P. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062753 · Cited by 4
“A rate limiting step in the transduction of certain cell lines by rAAV2 is the proteosomal degradation of vector capsids secondary to phosphorylation, and subsequent polyubiquitination, of surface exposed tyrosine residues by epidermal growth factor receptor protein tyrosine kinase [38].”
BackgroundViral Vectors for Gene Delivery
Dismuke, D. J., Gray, S. J., Hirsch, M. L., Samulski, R. J., & Muzyczka, N. (2010) · Royal Society of Chemistry eBooks · doi:10.1039/9781849732239-00338 · Cited by 3
Self-citationAhmadiankia, N., Neshati, V., Neshati, Z., Swildens, J., & de Vries, A. A. F. (2013) · PubMed Central · Cited by 2
Disease-specific interventions: The use of cell and gene therapies for Parkinson disease
Barker, R. A., & Buttery, P. C. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00003-4 · Cited by 2
Navigating the Hurdles of Intra-Articular AAV Gene Therapy
Li, W., Thornton, O. R., Feng, S. L., & Li, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010123 · Cited by 2
“…as well as hydrogen bonding, which changes the stability of the capsid, or post-translational modification processes, including acetylation, phosphorylation, ubiquitination, SUMOylation, and so on [32], which decrease the proteasome-mediated degradation and enhance trafficking to Golgi [33].”
Wang, K., Zheng, M., Askew, C., Zhang, X., Li, C., & Han, Z. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200128 · Cited by 3
Yuan, Y., Kong, W., Liu, X., & Shi, G. (2023) · Current Medical Science · doi:10.1007/s11596-022-2684-3 · Cited by 2
Luo, L., Xu, J., Wang, B.-Q., Chen, C., Chen, X., Hu, Q., Wang, Y., Zhang, W.-Y., Jiang, W., Li, X.-T., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122403 · Cited by 2
Bleomycin promotes rAAV2 transduction via DNA-PKcs/Artemis-mediated DNA break repair pathways
Huang, X., Wang, X., Sun, Y., Li, L., Li, A., Xu, W., Xie, X., & Diao, Y. (2023) · Virology · doi:10.1016/j.virol.2023.109959 · Cited by 2
AAV-based vectors for human diseases modeling in laboratory animals
Aliev, T. I., & Yudkin, D. V. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1499605 · Cited by 3
Chansel‐Debordeaux, L., Bourdenx, M., Dutheil, N., Doveró, S., Canron, M., Jimenez, C., Bézard, E., & Dehay, B. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.192.r3 · Cited by 2
The hybrid AAVP tool gets an upgrade
Alves-Cruzeiro, J., Webster, C. P., & Azzouz, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912635116 · Cited by 2
Bio-Production of Adeno-Associated Virus for Gene Therapy
Donohue, N., Keogh, N., Boi, S., & Barron, N. (2021) · Cell engineering · doi:10.1007/978-3-030-79871-0_11 · Cited by 1
Enhanced Cochlear Transduction by AAV9 with High-Concentration Sucrose
Noda, M., Koshu, R., Shimada, M. D., Saito, C., Takino, N., Ito, M., Yoshimura, H., Itō, M., & Muramatsu, S. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.111 · Cited by 1
Jin, J., Wang, W., Gao, T., Dai, Y., Tao, L., Ma, Q., Wang, L., Li, X., Chen, H., & Zhou, Y. F. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.117112 · Cited by 1
Recent advancements in improving cross-species applicability of bioengineered AAV capsids
Pan, H., Li, N., Qi, J., & Chai, R. (2026) · Gene Therapy · doi:10.1038/s41434-026-00628-y · Cited by 1
“Rational design, one of the earliest and most knowledge-driven strategies for AAV engineering, relies on detailed structural and biochemical knowledge of AAV to identify candidate positions on the capsid for bioengineering [22, 23].”
Zielinska, N., Howard, E. L., Stevens, B. A. Y., Goens, M. M., Campbell, E. S. B., Hughes, M. E., Pei, Y., Xu, L., Achuthan, A., Vadivel, A., et al. (2026) · Gene Therapy · doi:10.1038/s41434-026-00629-x · Cited by 1
Transfection of Cultured Primary Neurons
Rossi, A., Dahm, R., & Macchi, P. (2017) · Neuromethods · doi:10.1007/978-1-4939-7024-7_4 · Cited by 2
Viral‐Mediated Delivery of shRNA and miRNA
Manfredsson, F. P. (2013) · Wiley eBooks · doi:10.1002/9781118610749.ch11 · Cited by 2
Immune System Obstacles to In vivo Gene Transfer with Adeno-Associated Virus Vectors
Büning, H., & Mingozzi, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00004-x · Cited by 1
New innovations for ocular gene therapy
Igarashi, T., Miyake, K., Kobayashi, M., Takahashi, K., Nakamoto, K., Okada, T., & Takahashi, H. (2017) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.13.88 · Cited by 1
A novel and highly efficient AAV6 mutant
Wang, F., Huang, C., Cao, J., Liu, X., Wang, D., Zhang, C., & Chen, Q. (2017) · Virus Genes · doi:10.1007/s11262-017-1531-2 · Cited by 1
Expressing Full-Length Dystrophin Using Adeno-Associated Virus
Kodippili, K., & Duan, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00013-2 · Cited by 1
Viral Vectors for Muscle Gene Therapy
Wang, D., Brown, A., & Gao, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_10 · Cited by 1
Views of a Vector: An Interview with Mavis Agbandje-McKenna
Davies, K. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.29122.int · Cited by 1
Asghar, A., Asjad, Z., Tahir, H., Maheen, Z., & Hanif, S. (2021) · Pakistan Journal of Intensive Care Medicine · doi:10.54112/pjicm.v2021i1.6 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1
Metadata
- Authors
- Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., Muzyczka, N., & Srivastava, A.
- Affiliations
- *Division of Cellular and Molecular Therapy, Department of Pediatrics,
- Powell Gene Therapy Center and Genetics Institute,
- University of Florida Health (US)
- UF Health Cancer Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-06-03
- Volume
- 105
- Issue
- 22
- Pages
- 7827-7832
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2402387
- OpenAlex
- W2122236774
- Cited by
- 558
- References
- 53
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 30 · 2023: 31 · 2022: 29 · 2021: 43 · 2020: 38 · 2019: 31 · 2018: 27 · 2017: 34 · 2016: 29 · 2015: 38 · 2014: 34 · 2013: 44 · 2012: 24
- FWCI
- 18.28
- Type
- journal article
- Language
- en
- Update notices
- correction (2008-08-05)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- National Institutes of Health (Project 3)
- National Heart, Lung, and Blood Institute (P01-HL51811, P01HL059412, P01HL051811, R01 HL-07691, R01HL065570, R01HL-65570, P01HL078810)
- National Institute of General Medical Sciences (R01GM082946)
- National Institute of Allergy and Infectious Diseases (R01AI051390)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, R01DK062302)
- National Institute of Biomedical Imaging and Bioengineering (R01EB002073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- tyrosine mutations, proteasomal degradation, nuclear transport, transduction efficiency, factor IX, gene therapy vectors, hepatocytes
- MeSH terms
- Dependovirus, Animals, Capsid, Cell Nucleus, Genetic Vectors, HeLa Cells, Humans, Mice, Inbred C57BL, Phosphorylation, Transduction, Genetic, Tyrosine, Genetic Therapy, Point Mutation, Hepatocytes, Mice, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.